A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

This study has been completed.
Information provided by (Responsible Party):
ViiV Healthcare
ClinicalTrials.gov Identifier:
First received: December 16, 2010
Last updated: June 16, 2016
Last verified: June 2016

December 16, 2010
June 16, 2016
February 2011
May 2012   (final data collection date for primary outcome measure)
Percentage of Participants With Plasma Human Immunodeficiency Virus -1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48 [ Time Frame: Week 48 ] [ Designated as safety issue: No ]
The percentage of participants with plasma HIV-1 RNA <50 c/mL at Week 48 was assessed. Plasma samples were collected for the quantitative assessment of HIV-1 RNA based on the Missing, Switch, or Discontinuation equals Failure (MSDF) algorithm,as codified by the Food and Drug Administration's Snapshot algorithm. This algorithm treats all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigationl product prior to the visit window) as non-responders, as well as participants who switched their concomitant antiretroviral therapy (ART) in certain scenarios. Since changes in ART were not permitted in this protocol, all such participants who changed ART were to be considered non-responders. Otherwise, virologic success or failure was to be determined by the last available HIV-1 RNA assessment while the participant was on treatment within the visit of interest window.
The primary efficacy endpoint is the proportion of subjects achieving and maintaining confirmed HIV-1 RNA less than 50 copies/mL through Week 48 [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01263015 on ClinicalTrials.gov Archive Site
  • Time to Viral Suppression (<50 c/mL) [ Time Frame: From Baseline until data cut off for Week 48 analysis (average of 357.0 days for DTG; average of 332.2 study days for EFV/TDF/FTC) ] [ Designated as safety issue: No ]
    Viral suppression is defined as the first viral load value<50 c/mL. The Kaplan-Meier method was used to estimate time to viral suppression, defined as the time from the first dose of study treatment until the first viral load value <50 c/mL was reached. Participants who withdrew for any reason without having suppressed prior to the analysis were censored.
  • Number of Participants With a Confirmed Plasma HIV-1 RNA Level >=1000 c/mL at or After Week 16 and Before Week 24, or a Confirmed Plasma HIV-1 RNA Level >=200 c/mL at or After Week 24 [ Time Frame: From Baseline until data cut off for the Week 48 analysis (average of 357.0 study days for DTG; average of 332.2 study days for EFV/TDF/FTC) ] [ Designated as safety issue: No ]
    Data are presented as Kaplan Meier estimates of virologic failure (VF), defined as a confirmed plasma HIV-1 RNA level >=1000 c/mL at or after Week 16 and before Week 24, or a confirmed plasma HIV-1 RNA level >=200 c/mL at or after Week 24. A plasma HIV-1 RNA value was considered to be confirmed failure if a consecutive measurement satisfied the same failure criterion. The number of participants who experienced autoimmune deficiency syndrome (AIDS) Clinical Trials Group (ACTG) VFs was measured. For participants who withdrew from the study/were not documented to have reached confirmed VF at the cut off date of the Week 48 analysis, time to VF was to be censored at the planned visit week of the last measured plasma HIV-1 RNA sample. Data for participants who missed three consecutive scheduled plasma HIV-1 RNA measurements were to be censored at the planned visit week of the last assessment prior to the 3 consecutive missed visits.
  • Change From Baseline in Plasma HIV-1 RNA at Weeks 4, 8, 12, 24, 32, and 48 [ Time Frame: Baseline and Weeks 4, 8, 12, 24, 32, and 48 ] [ Designated as safety issue: No ]
    Blood samples were collected for the measurement of HIV-1 RNA in plasma. Changes from Baseline was calculated as the post-Baseline value minus the Baseline value.
  • Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Counts at Week 48 [ Time Frame: Baseline and Week 48 ] [ Designated as safety issue: No ]
    CD4 lymphocyte cells (also called T-cells or T-helper cells) are the primary targets of HIV. The CD4 count and the CD4 percentage mark the degree of immunocompromise. The CD4 count is used to stage the patient's disease, determine the risk of opportunistic illnesses, assess prognosis, and guide decisions about when to start antiretroviral therapy. Change from Baseline was calculated as the Week 48 value minus the Baseline value. The least squares mean is the estimated mean change from Baseline in CD4+ cell counts at Week 48 calculated from a repeated measures model including the following covariates: treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, treatment*visit interaction, Baseline HIV-1 RNA*visit interaction, and Baseline CD4+ cell count*visit interaction. No assumptions were made about the correlations between a participant's readings of CD4+, i.e., the correlation matrix for within-participant errors is unstructured.
  • Number of Participants With the Indicated Post-baseline HIV-associated Conditions and Progression, Excluding Recurrences [ Time Frame: From Baseline until Week 48 ] [ Designated as safety issue: No ]
    Clinical disease progression (CDP) was assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the AIDS surveillance case definition. Indicators of CDP were defined as: CDC CAT A at Baseline (BS) to a CDC CAT C event (EV); CDC CAT B at BS to a CDC CAT C EV; CDC CAT C at BS to a new CDC CAT C EV; or CDC CAT A, B, or C at BS to death.
  • Number of Participants With the Indicated Grade 1 to 4 Clinical and Hematology Toxicities [ Time Frame: From Baseline until data cut off for the Week 48 analysis (average of 357.0 study days for DTG; average of 332.2 study days for EFV/TDF/FTC) ] [ Designated as safety issue: No ]
    All Grade 1 to 4 post-Baseline-emergent chemistry toxicities included alanine aminotransferase (ALT), albumin, alkaline phosphatase (ALP), asparate aminotransferase (AST), carbon dioxide (CO2) content/bicarbonate, cholesterol, creatine kinase (CK), creatinine, hyperglycemia, hyperkalemia, hypernatremia, hypoglycemia, hypokalemia, hyponatremia, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphorus inorganic, total bilirubin, and triglycerides. All Grade 1 to 4 post-Baseline-emergent hematology toxities included hemoglobin, platelet count, total neutrophils, and white blood cell count. The Division of AIDS (DAIDS) defined toxicity grades as follows: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening; Grade 5, death.
  • Number of Participants With the Indicated Genotypic Resistance With Virological Failure (VF) [ Time Frame: Baseline to the time of virological failure (up to Week 48) ] [ Designated as safety issue: No ]
    Whole blood samples were collected from participants to provide plasma for storage samples for potential viral genotypic and phenotypic analyses. Participants with confirmed virological failure (confirmed HIV-1 RNA >=50 copies/mL throughout the study and/or confirmed HIV-1 RNA >=200 copies/mL at Week 48) had plasma samples tested for HIV-1 RT genotype and HIV-1 integrase genotype from Baseline samples and from samples collected at the time of virological failure. Genotype testing was conducted at Day 1 and at the time of suspected protocol-defined virological failure (PDVF). A genotyping assessment was made of change across all amino acids within the integrase (IN)-encoding region, with particular attention paid to specific amino acid changes associated with the development of resistance to RAL, ELV, or DTG.
  • Change From Baseline in the Symptom Bother Score (SBS) at Week 4 [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
    The Symptom Distress Module (SDM) is a 20-item, self-reported questionnaire measuring the presence/perceived distress linked to symptoms associated with HIV/its treatments. Developed with support from the AIDS Clinical Trials Group of the U.S. National Institute of Allergy and Infectious Diseases, it has demonstrated construct validity and has shown strong associations with physical/mental health summary scores and with disease severity. The SDM consists of 2 main scores: symptom count and the SBS, ranging from 0 (best) to 80 (worst) and based on the degree of bother that each symptom present posed. The SBS was calculated by adding the 20 individual bother item scores, which were calculated as: 0, "I do not have this symptom"; 1, "It doesn't bother me"; 2, "It bothers me a little"; 3, "It bothers me"; 4, "It bothers me a lot." Estimates are calculated from an analysis of covariance (ANCOVA) model adjusting for age, sex, race, Baseline (BL) viral load, BL CD4+ cell count, and BL SBS.
  • To evaluate the efficacy of the treatment arms over time using proportions of subjects maintaining plasma HIV-1 RNA <50copies/mL to Week 96 as well as change from baseline in HIV-1 RNA and increases in CD4+ cell counts [ Time Frame: 48 and 96 weeks ] [ Designated as safety issue: No ]
  • To evaluate the number of participants with clinical or laboratory adverse events as a measure of safety and tolerability of the two treatment arms [ Time Frame: 48 and 96 Weeks ] [ Designated as safety issue: No ]
  • To assess the development of viral resistance in subjects experiencing virological failure. [ Time Frame: 48 and 96 Weeks ] [ Designated as safety issue: No ]
  • To evaluate the incidence of HIV-associated conditions. [ Time Frame: 48 and 96 Weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
The purpose of this trial is to assess the non-inferior antiviral activity of GSK1349572 50 mg plus Abacavir/Lamivudine once daily versus Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate (ATRIPLA® a trade mark of Bristol-Myers Squibb and Gilead Sciences LLC) over 48 weeks; non-inferiority will also be tested at Week 96. This study will be conducted in HIV-1 infected ART-naïve adult subjects. Long term antiviral activity, tolerability, safety, and development of viral resistance will be evaluated.

ING114467 is a Phase 3 randomized, double-blind, double dummy, active-controlled, multicenter, study conducted in approximately 788 HIV-1 infected ART-naïve subjects. Subjects will be randomized 1:1 one of the following treatment arms:

GSK1349572 50 mg plus abacavir/lamivudine fixed-dose combination once daily (approximately 394 subjects)


Atripla once daily (approximately 394 subjects)

Analyses will be conducted at 48 weeks and 96 weeks. Subjects randomized to receive GSK1349572 and who successfully complete 96 weeks of treatment will continue to have access to GSK1349572 plus abacavir/lamivudine fixed-dose combination through the study until it is locally available-as long as they continue to derive clinical benefit, until they meet a protocol-defined reason for discontinuation, or until development of the compound is terminated.

ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship

Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Infection, Human Immunodeficiency Virus I
  • Drug: Dolutegravir
    Dolutegravir (also known as GSK1349572) 50 mg taken once daily
  • Drug: Atripla
    Atripla once daily on an empty stomach
  • Drug: Abacavir/Lamivudine
    taken once daily; also known as EPZICOM
  • Drug: Abacavir/Lamivudine Placebo
    matching placebo taken once daily
  • Drug: Dolutegravir placebo
    matching placebo taken once daily
  • Drug: Atripla placebo
    matching placebo taken once daily on an empty stomach
  • Experimental: Dolutegravir (N=~394):
    Dolutegravir 50mg once daily + abacavir/lamivudine as the fixed-dose combination once daily + Atripla placebo once daily
    • Drug: Dolutegravir
    • Drug: Abacavir/Lamivudine
    • Drug: Atripla placebo
  • Active Comparator: Atripla (N=~394):
    Atripla once daily + Dolutegravir placebo once daily + abacavir/lamivudine as the fixed-dose combination placebo once daily
    • Drug: Atripla
    • Drug: Abacavir/Lamivudine Placebo
    • Drug: Dolutegravir placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2015
May 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Screening plasma HIV-1 RNA ≥1000 c/mL
  • Antiretroviral-naïve (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection)
  • Ability to understand and sign a written informed consent form
  • Willingness to use approved methods of contraception to avoid pregnancy (women of child bearing potential only)
  • Age equal to or greater than 18 years
  • A negative HLAB*5701 allele assessment

Exclusion Criteria:

  • Women who are pregnant or breastfeeding;
  • Active Center for Disease and Prevention Control (CDC) Category C disease
  • Hepatic impairment
  • HBV co-infection
  • Anticipated need for HCV therapy during the study
  • Allergy or intolerance to the study drugs or their components or drugs of their class
  • Malignancy within the past 5 years
  • Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening
  • Treatment with radiation therapy, cytotoxic chemotherapeutic agents or any immunomodulator within 28 days of Screening
  • Exposure to an agent with documented activity against HIV-1 in vitro or an experimental vaccine or drug within 28 days of first dose of study medication
  • Primary viral resistance in the Screening result
  • Verified Grade 4 laboratory abnormality
  • ALT >5 xULN
  • ALT ≥ 3xULN and bilirubin ≥ 1.5xULN (with >35% direct bilirubin);
  • Estimated creatinine clearance <50 mL/min
  • Recent history (≤3 months) of upper or lower gastrointestinal bleed
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Belgium,   Canada,   Denmark,   France,   Germany,   Italy,   Netherlands,   Romania,   Spain,   United Kingdom
Poland,   South Africa
Not Provided
Not Provided
ViiV Healthcare
ViiV Healthcare
  • Shionogi
  • GlaxoSmithKline
Study Director: GSK Clinical Trials ViiV Healthcare
ViiV Healthcare
June 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP